Tamura et al. [1111 Maganhin CC, Fuchs LF, Simoes RS, Oliveira-Filho RM, de Jesus Simões M, Baracat EC, et al. Effects of melatonin on ovarian follicles. Eur J Obstet Gynecol Reprod Biol 2013;166(2):178–84.] |
2008 |
Controlled Clinical Trial |
IVF ET |
3 mg/day |
The study has results that melatonin improves among other aspects of ARTs and fertility rates |
improves oocyte and embryo quality and better fertility taxes. |
Unfer et al. [1919 Jing T, Shile S, Sun Y, Li H, Li WP, Cong Z, et al. Melatonin levels in follicular fluid as markers for IVF outcomes and predicting ovarian reserve. Reproduction 2017;153 (4):443–51.] |
2011 |
Clinical Trial |
IVF |
3 mg/day |
The study has results that melatonin improves oocyte quality |
had improved on pregnancy rate |
Batioglu et al. [1818(Professor of SR and P Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, et al. Writer on evidence-based medicine. In: Page MJ, ed. Cochrane Handbook For Systematic Reviews of Interventions; 2023. p. 694.] |
2012 |
Randomized Controlled Trial |
IVF ET |
3 mg/day |
The justification for the inclusion is the efficacy of melatonin administered in improving oocyte quality |
improves oocyte and embryo quality |
Fernando et al. [1717 Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.] |
2014 |
Clinical Trial |
IVF ICSI |
4 mg/twice per day |
Double-blind randomized study evaluating melatonin in infertility treatments |
Melatonin in ART will be the first trial designed to determine a relationship of melatonin on clinical pregnancy rates. |
Nishihara et al. [2020 Fernando S, Osianlis T, Vollenhoven B, Wallace E, Rombauts L. A pilot double-blind randomised placebo-controlled dose-response trial assessing the effects of melatonin on infertility treatment (MIART): study protocol. BMJ Open 2014;4(8):e005986.] |
2014 |
Clinical Trial |
IVF |
3 mg/day |
The justification for the inclusion is the efficacy of melatonin administered in improving oocyte quality |
improves oocyte and embryo quality |
Jahromi et al. [2121 Batiioǧlu AS, Şahin U, Grlek B, Öztrk N, Ünsal E. The efficacy of melatonin administration on oocyte quality. Gynecol Endocrinol 2012;28(2):91–3.] |
2017 |
Randomized Controlled Trial |
IVF |
3 mg/day |
Double-blind randomized study evaluating melatonin in infertility treatments in women with low ovarian reserve |
improves oocyte and embryo quality |
Tong et al. [2222 Espino J, Macedo M, Lozano G, Ortiz Á, Rodríguez C, Rodríguez AB, et al. Impact of melatonin supplementation in women with unexplained infertility undergoing fertility treatment. Antioxidants 2019;8(9):338.] |
2017 |
Clinical Trial |
IVF ICSI |
Melatonin measument in folicular fluid with range was 2.3‒1000 pg/mL. |
The justification for the inclusion is that melatonin levels can be markers and predictors of low ovarian reserve and better results in IVF |
improves oocyte and embryo quality |
Zheng et al. [2323 Tong J, Sheng S, Sun Y, Li H, Li WP, Zhang C, et al. Melatonin levels in follicular fluid as markers for IVF outcomes and predicting ovarian reserve. Reproduction 2017;153 (4):443–51.] |
2017 |
Clinical Trial |
IVF |
Melatonin measument in folicular fluid. |
The work seals the concentrations of melatonin in the follicular fluids and their role in human reproduction |
We have demonstrated that higher folicullar fluid melatonin concentrations were related to better ART outcomes |
Ma et al. [2424 Zheng M, Tong J, Li WP, Chen ZJ, Zhang C. Melatonin concentration in follicular fluid is correlated with antral follicle count (AFC) and in vitro fertilization (IVF) outcomes in women undergoing assisted reproductive technology (ART) procedures. Gynecol Endocrinol 2018;34(5):446–50.] |
2018 |
Clinical Trial |
IVF ICSI ET |
|
This study was the only one that did not have the presence of melatonin, therefore it was important for the inclusion criteria in the present systematic review because it worked with studies of two fluids of two follicular follicles in women with ovarian hyperstimulation syndrome. |
Follicle count measured on the day of hCG administration was the only predictive factor for the occurrence of OHSS |
Espino et al. [2525 Jahromi BN, Sadeghi S, Alipour S, Mohammad, Parsanezhad E, Alamdarloo SM. Effect of melatonin on the outcome of assisted reproductive technique cycles in women with diminished ovarian reserve: a double-blinded randomized clinical trial. Irian J Med Sci 2017;42(1):73–8.] |
2019 |
Clinical Trial |
IVF |
3 mg/day or 6 mg/ day |
The authors studied the use of melatonin in infertilities with no apparent or apparent cause in unexplained infertilities |
improves oocyte and embryo quality |
Fernando et al. [2626 Unfer V, Raffone E, Rizzo P, Buffo S. Effect of a supplementation with myo-inositol plus melatonin on oocyte quality in women who failed to conceive in previous in vitro fertilization cycles for poor oocyte quality: a prospective, longitudinal, cohort study. Gynecol Endocrinol 2011;27(11):857–61.] |
2019 |
Randomized Controlled Trial |
IVF |
2, 4 or 8 mg/twice a day |
This work, despite having arguments that go against current literature, is important for studying melatonin in ovarian vascular indices |
Melatonin and vascular indices cannot predict the number or quality of oocytes or embryos obtained in an IVF cycle. |
Li et al. [2727 Ma T, Niu Y, Wei B, Xu L, Zou L, Che X, et al. Moderate-to-severe ovarian hyperstimulation syndrome: a retrospective multivariate logistic regression analysis in Chinese patients. Adv Clin Exp Med 2020;29(1):85–90.] |
2019 |
Case control Study |
IVF ICSI ET |
Melatonin measument in folicular fluid. |
The authors studied in the same work the functions of melatonin in ovarian hyperstimulation syndrome |
Role of melatonin as a predictor of ovarian hyperstimulation syndrome |
Zheng et al. [2828 Fernando S, Wallace EM, Rombauts L, White N, Hong J, Vollenhoven B, et al. The effect of melatonin on ultrasound markers of follicular development: a double-blind placebo-controlled randomised trial. Aust N Z J Obstet Gynaecol 2020;60(1):141–8.] |
2019 |
Clinical Trial |
IVF |
Melatonin measument in folicular fluid |
This work was important to be selected because it was the first to demonstrate that melatonin in the follicular fluids is significantly increased in women with OHSS |
The authors studied in the same work the functions of melatonin in ovarian hyperstimulation syndrome |
Espinola et al. [2929 Li Y, Fang L, Yu Y, Shi H, Wang S, Guo Y, et al. Higher melatonin in the follicle fluid and MT2 expression in the granulosa cells contribute to the OHSS occurrence. Reproductive Biology and Endocrinology 2019;17(1):37.] |
2020 |
Prospective Randomized and Controlled Pilot Study |
IVF |
1 mg/day |
As justifications for the inclusion of this work, there is a randomized study that studied vitamin D, melatonin, or myo-inositol and folic acid in assisted reproduction |
The main failure was that increased vitamin D levels were positively correlated with IVF implantation rates. |
Wdowiak et al. [3030 Bezerra Espinola MS, Bilotta G, Aragona C. Positive effect of a new supplementation of vitamin D3 with myo-inositol, folic acid and melatonin on IVF outcomes: a prospective randomized and controlled pilot study. Gynecol Endocrinol 2021;37 (3):251–4.] |
2020 |
Prospective Randomized and Controlled Trial |
IVF ICSI |
1 mg/day |
A study comparing other two substances together with melatonin in women with OHSS |
A combination of myo-inositol, vitamin D and melatonin including better fertilization and pregnancy outcomes as well as reduced risk of OHSS |
Li et al. [3131 Wdowiak A, Filip M. The effect of myo-inositol, vitamin D3 and melatonin on the oocyte quality and pregnancy in in vitro fertilization: a randomized prospective controlled trial. Eur Rev Med Pharmacol Sci 2020;24(16):8529–36.] |
2021 |
Randomized Controlled Trial |
IVF IVM |
MT in fluid folicular in IVF and addition in vitro culture of 10–5 mol/L melatonina in IVM. |
It was a pilot study that compared IVF protocols with in vitro maturation and the presence of melatonin and its results in human reproduction. |
Melatonin supplementation has efficacy in clinical results of assisted reproduction as higher rates of oocytes in IVF |
Zheng et al. [3232 Li X, Mu Y, Elshewy N, Ding D, Zou H, Chen B, et al. Comparison of IVF and IVM outcomes in the same patient treated with a modified IVM protocol along with an oocytes-maturing system containing melatonin: a pilot study. Life Sci 2021;264:118706.] |
2022 |
Clinical Trial |
– |
Melatonin treatment in 10 μM cell culture |
The authors studies the functions of melatonin in ovarian hyperstimulation syndrome |
Melatonin attenuated reactive oxygen species during apoptosis |